WO2013032231A3 - Pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor - Google Patents

Pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor Download PDF

Info

Publication number
WO2013032231A3
WO2013032231A3 PCT/KR2012/006910 KR2012006910W WO2013032231A3 WO 2013032231 A3 WO2013032231 A3 WO 2013032231A3 KR 2012006910 W KR2012006910 W KR 2012006910W WO 2013032231 A3 WO2013032231 A3 WO 2013032231A3
Authority
WO
WIPO (PCT)
Prior art keywords
microrna
inhibitor
angiogenic composition
composition including
present
Prior art date
Application number
PCT/KR2012/006910
Other languages
French (fr)
Korean (ko)
Other versions
WO2013032231A2 (en
Inventor
이유미
Original Assignee
경북대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경북대학교 산학협력단 filed Critical 경북대학교 산학협력단
Priority to US14/240,539 priority Critical patent/US9012426B2/en
Priority claimed from KR20120094794A external-priority patent/KR20130024831A/en
Publication of WO2013032231A2 publication Critical patent/WO2013032231A2/en
Publication of WO2013032231A3 publication Critical patent/WO2013032231A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an anti-angiogenic composition, and more particularly, to a pharmaceutical anti-angiogenic composition including a microRNA-382 inhibitor. The inventors of the present invention have confirmed that microRNA-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis induced in a low oxygen environment. Therefore, the pharmaceutical composition of the present invention inhibits microRNA-382 and thus inhibits angiogenesis and cell proliferation, and is expected ultimately to be valuably used in the treatment of cancer.
PCT/KR2012/006910 2011-08-30 2012-08-29 Pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor WO2013032231A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/240,539 US9012426B2 (en) 2011-08-30 2012-08-29 Pharmaceutical anti-angiogenic composition including a MicroRNA-382 inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0086987 2011-08-30
KR20110086987 2011-08-30
KR20120094794A KR20130024831A (en) 2011-08-30 2012-08-29 Pharmaceutical composition comprising microrna-382 inhibitor for inhibiting angiogenesis
KR10-2012-0094794 2012-08-29

Publications (2)

Publication Number Publication Date
WO2013032231A2 WO2013032231A2 (en) 2013-03-07
WO2013032231A3 true WO2013032231A3 (en) 2013-05-10

Family

ID=47757054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006910 WO2013032231A2 (en) 2011-08-30 2012-08-29 Pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor

Country Status (1)

Country Link
WO (1) WO2013032231A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014008A2 (en) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
KR20100009268A (en) * 2008-07-18 2010-01-27 국립암센터 Anti-cancer composition comprising microrna molecules
US20110184043A1 (en) * 2008-04-07 2011-07-28 Cornell Research Foundation, Inc. Inhibition of angiogenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014008A2 (en) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
US20110184043A1 (en) * 2008-04-07 2011-07-28 Cornell Research Foundation, Inc. Inhibition of angiogenesis
KR20100009268A (en) * 2008-07-18 2010-01-27 국립암센터 Anti-cancer composition comprising microrna molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM, MIN JEONG: "The roles of microRNA-382 induced by hypoxia in angiogenesis master's thesis", KYUNKPOOK NATIONAL UNIVERSITY GRADUATE SCHOOL, June 2010 (2010-06-01) *

Also Published As

Publication number Publication date
WO2013032231A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
IN2015DN03795A (en)
MX2019010602A (en) Cdk inhibitors.
TN2012000280A1 (en) Methods of administering pirfenidone therapy
DOP2015000039A (en) GLUCOSILCERAMIDE SINTASA INHIBITORS
WO2012104007A3 (en) 7-azaindole derivatives
MX2019008428A (en) Glucosylceramide synthase inhibitors.
MX2011007420A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells.
TW201711676A (en) Ferric citrate dosage forms
HK1195299A1 (en) Azetidine compounds, compositions and their use as inhibitors of soluble epoxide hydrolase
MX2014005721A (en) 2-thiopyrimidinones.
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
WO2011056021A3 (en) Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis
WO2012065139A8 (en) Entpd5 inhibitors
GB2502032A (en) Vitamin D composition
MX2012001306A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists.
IN2014DN06104A (en)
NZ711564A (en) Methods of treating colorectal cancer
WO2010030835A3 (en) Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
TR201009167A2 (en) Pharmaceutical granules containing cephalosporin.
IN2014DN00123A (en)
EP2920311A4 (en) Methods and compositions for processing biomass with elevated levels of starch
WO2013032231A3 (en) Pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor
MX2013005699A (en) Stable preserved compositions if interferon-beta.
MX2012006614A (en) Suppository comprising pantoprazole.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12828326

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14240539

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12828326

Country of ref document: EP

Kind code of ref document: A2